

JLR: FY26 margin and FCF guidance curtailed

Auto & Auto Ancillaries ▶ Analyst Meet Update ▶ June 17, 2025

CMP (Rs): 687 | TP (Rs): 750

We attended JLR's Annual Investor Day meet to understand its outlook and growth strategy. **KTAs:** i) JLR gave guidance for £28bn revenue with 5-7% EBIT margin in FY26 (vs earlier guidance of 10%; FY25: 8.5%); it maintained its interim/long-term guidance of 10%/15%, led by sustained focus on premiumization (growing share of higher-priced models), pricing discipline, and structural cost reduction. 2) FY26 FCF to be 'close to zero' vs £1.5bn in FY25 on lower profitability, drag from working capital, and sustained investment spends of £3.8bn (akin to FY25; previous guidance above £3.5bn). 3) JLR has factored in a potential trade between US and both, UK and EU; any delay could see margin pressure in H1FY26. 4) Amid slower than anticipated BEV adoption and changing emission regulations, JLR is increasing investments in ICE, on extended visibility; *Jaguar* to be fully electric; *Range Rover* EV launch planned for CY26. 5) JLR's SDVs, with next-gen EV architecture, can boost processing power by 15x and cut wiring harness content by ~60%. 6) JLR has outpaced the Chinese premium PV market, and aims to maintain the pace via multiple targeted initiatives. We cut FY26E/27E consol EPS by ~15%, to factor in the challenging demand environment at JLR and the curtailed EBIT margin guidance. We build in £27.5bn revenue (5% YoY fall) with 6.4% EBIT margin and FCF of -£528mn. Over the last 5 years, JLR has significantly strengthened its business profile (largely resilient volume, high profitability) and balance sheet (net cash), thus positioning itself well to withstand near-term challenges. We maintain BUY on TTMT while trimming out SoTP-based TP by ~6% to Rs750.

KTAs from the Analyst Meet

1) The mgmt guided to ~£28bn revenue, 5-7% EBIT margin in FY26 (vs 10% earlier); it upheld its 10%/15% interim/LT guidance, on sustained focus on premiumization, pricing discipline, structural cost reduction. Gross margin to benefit from richer mix (ASP at over £70k vs ~£45k in FY19), though headwinds from US tariffs and China-related challenges could weigh on FY26 EBITDA; JLR's guidance factors in a potential trade deal between US and both—EU and UK, and any delay could hit margin in H1FY26. 2) JLR reaffirmed investment guidance of £18bn over FY24-28 (~50% to be allocated to engineering, ie platforms, EVs). JLR's FY26 FCF guidance "close to zero" vs £1.5bn in FY25 amid lower profitability, ~£3.8bn investment (akin to FY25), and drag from working capital. 3) Amid slower than anticipated BEV adoption, JLR's investment focus to shift back to ICE in the near term (will not rush BEV launches; *Range Rover* EV planned for CY26); *Jaguar* to be fully electric. 4) Apart from other headwinds like trade protectionism (US tariffs) and weakening dollar, technical protectionism is seen driving up investments, as US and China are rejecting each other's ADAS technologies which necessitates parallel development (higher development costs). 5) JLR is prioritizing software defined vehicles (SDVs), with its next-gen EV architecture seen delivering 15x more processing power, cutting wiring harness content ~60%, and reducing semi-conductor dependence 80%. 6) China's premium PV market stays under pressure (down 15% in FY25) amid macro-led demand contraction, intense price wars (215 models saw price cuts in CY24), and heightened competition. 7) JLR aims to revive *Freelander* brand (new EV model launch in H2CY26).

Tata Motors: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Revenue	3,459,670	4,340,160	4,396,950	4,478,910	4,594,941
EBITDA	318,296	578,720	551,320	493,989	509,407
Adj. PAT	7,336	330,471	225,030	206,272	217,015
Adj. EPS (Rs)	1.9	86.2	61.2	56.1	59.0
EBITDA margin (%)	9.2	13.3	12.5	11.0	11.1
EBITDA growth (%)	28.3	0	(4.7)	(10.4)	3.1
Adj. EPS growth (%)	0	0	(29.1)	(8.3)	5.2
RoE (%)	1.6	77.8	22.4	16.5	15.1
RoIC (%)	3.0	92.9	38.6	42.9	32.1
P/E (x)	108.9	8.2	11.0	12.2	11.6
EV/EBITDA (x)	10.4	5.2	4.4	5.0	4.9
P/B (x)	5.8	3.1	2.2	1.9	1.6
FCFF yield (%)	5.3	12.3	10.6	1.7	2.0

Source: Company, Emkay Research

Target Price – 12M	Mar-26
Change in TP (%)	(6.3)
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	9.2

Stock Data	TTMT IN
52-week High (Rs)	1,179
52-week Low (Rs)	536
Shares outstanding (mn)	3,681.5
Market-cap (Rs bn)	2,528
Market-cap (USD mn)	29,373
Net-debt, FY26E (Rs mn)	(38,939.8)
ADTV-3M (mn shares)	16
ADTV-3M (Rs mn)	11,449.7
ADTV-3M (USD mn)	133.0
Free float (%)	57.4
Nifty-50	24,946.5
INR/USD	86.1

Shareholding, Mar-25

Promoters (%)	42.6
FPIs/MFs (%)	17.8/17.1

Price Performance

(%)	1M	3M	12M
Absolute	(6.0)	4.8	(30.9)
Rel. to Nifty	(5.8)	(5.5)	(35.0)

1-Year share price trend (Rs)



Chirag Jain

chirag.jain@emkayglobal.com
+91-22-66242428

Jaimin Desai

jaimin.desai@emkayglobal.com
+91-22-66121334

Nandan Pradhan

nandan.pradhan@emkayglobal.com
+91-22-66121238

Omkar Rane

omkar.rane@emkayglobal.com
+91-22-66242414

Marazbaan Dastur

marazbaan.dastur@emkayglobal.com
+91-22-66121281

This report is intended for Gaurav Narkar (gaurav.narkar@emkayglobal.com) use and downloaded at 06/18/2025 02:41 PM


Other highlights from the analyst meet

- Revived brand *Freelander* will offer a portfolio of electric vehicles for sale in China through a distinct retailer network; it is destined for global export, over time. This represents complementary growth, which is independent from both—Chery (CJLR)'s existing portfolio and JLR's modern luxury 'House of Brands'.
- JLR is also actively supporting dealer marketing amid a tough macro landscape (~4,400 retailers, ie 15% of the total dealers in China, ceased their operations in CY24).
- **Brand-wise performance**
 - **Range Rover:** Continued focus on addressing portfolio white spaces (launched multiple variants at different price-points) led to 37% YoY volume growth and 15% rise in order intake, in FY25. A robust EV waitlist of over 60,000 units underscores healthy demand visibility.
 - **Range Rover Sport:** Wholesales grew 39% YoY, with order intake rising 34% for the *Range Rover Sport* in FY25, reflecting strong market traction.
 - **Defender:** JLR has successfully repositioned *Defender* as a premium off-roader, and it now commands prices 3-4x above historical levels. The newly launched *Octa* variant (first edition priced at £165k) has received an encouraging initial response which shows customer willingness to pay a higher price.


Exhibit 1: JLR has seen strong improvement across operational parameters, despite low growth

Product mix (%)	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Land Rover	69	73	78	80	83	88	93
- of which: RR, RRS, Defender	25	24	36	40	48	63	68
Jaguar	31	27	22	20	17	12	7
ASP (£ mn)	47,675	48,291	56,758	62,274	70,976	72,252	72,240
Growth YoY (%)	1	1	18	10	14	2	(0)
EBITDA margin (%)	8.2	8.9	12.8	10.3	11.3	15.9	14.3
EBITDA/unit (£)	3,938	4,307	7,281	6,445	8,000	11,512	10,354
EBIT margin (%)	(0.8)	0.6	2.8	(0.3)	2.3	8.4	8.5
EBIT/unit (£)	(360)	294	1,597	(163)	1,646	6,093	6,171
FCF (£ mn)	(1,267)	(702)	184	(1,156)	519	2,269	1,478
Net Debt (£ mn)	736	2,220	1,915	3,199	2,997	732	(278)
Net Debt/EBITDA (x)	0.4	1.1	0.8	1.7	1.2	0.2	(0.1)
RoE (%)	0.9	(2.8)	0.6	(16.3)	(1.2)	44.7	20.3
RoCE (Pre-tax, %)	(1.4)	1.3	4.9	(0.4)	4.9	23.9	22.2


Source: Company, Emkay Research; Note: FCF and net debt are as per company presentation

Exhibit 2: On a consolidated basis, TTMT's automotive business is now net cash (net debt free)

Source: Company, Emkay Research

Exhibit 3: JLR has successfully achieved its FY25 net cash guidance

Source: Company, Emkay Research

Exhibit 4: JLR's net debt-to-equity stands at (0.03)x as of FY25

Source: Company, Emkay Research


This report is intended for Gaurav Narkar (gaurav.narkar@emkayglobal.com) use and downloaded at 06/18/2025 02:41 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


Exhibit 5: JLR has given guidance for 'near zero' FCF with 5-7% EBIT margin vs £1.5bn FCF and 8.5% EBIT margin in FY25

GUIDANCE	
	- FY26 EBIT in the range of 5% to 7%
	- FY26 Free cash flow close to zero
	- Improving year-on-year for FY27 and FY28
	- Enterprise missions (excluding tariffs) will progressively deliver £1.4b per annum <ul style="list-style-type: none"> - Builds over time to offset residual tariff, foreign exchange and China risk - Allows for return to 10% EBIT

Source: Company, Emkay Research

Exhibit 6: JLR has maintained its £3.8bn investment guidance for FY26


Source: Company, Emkay Research

Exhibit 7: JLR aims to remain flexible, aided by its strategic focus on multiple vehicle architectures


Source: Company, Emkay Research


This report is intended for Gaurav Narkar (gaurav.narkar@emkayglobal.com) use and downloaded at 06/18/2025 02:41 PM

Exhibit 8: JLR has identified multiple macro headwinds that could potentially weigh on its EBIT margin



Source: Company, Emkay Research

Exhibit 9: JLR's next-gen EV architecture would significantly boost the processing power while also reducing costs



Source: Company, Emkay Research

Exhibit 10: Amid a weaker PV market in China, JLR has outperformed in the higher segment



Source: Company, Emkay Research

Exhibit 11: JLR aims to continue outpacing the Chinese premium PV market led by several targeted initiatives



Source: Company, Emkay Research

Exhibit 12: We build in 2% consolidated revenue CAGR over FY25-27E

Particulars	FY22	FY23	FY24	FY25	FY26E	FY27E
Domestic MHCV sales (no of units; '000)	241	359	373	374	379	394
Growth YoY (%)	49.7	49.2	4.0	0.1	1.3	4.1
Domestic LCV sales (no of units; '000)	476	603	595	564	575	592
Growth YoY (%)	16.7	26.8	-1.4	-5.3	2.0	3.0
Domestic PV sales (no of units; '000)	3,070	3,890	4,218	4,328	4,506	4,788
Growth YoY (%)	13.2	26.7	8.4	2.6	4.1	6.3
Market share (%)	FY22	FY23	FY24	FY25	FY26E	FY27E
Domestic Trucks	54.1	49.6	49.5	49.3	50.4	50.3
Domestic Buses	38.3	29.8	29.9	32.7	33.3	33.9
LCVs	40.1	36.0	32.2	30.1	30.4	31.0
Domestic CV	44.6	40.3	37.8	36.6	37.0	37.4
PVs	12.2	14.0	13.8	13.2	12.9	12.7
Revenue Model...(Rs mn)	FY22	FY23	FY24	FY25	FY26E	FY27E
India CV volumes (no of units)	354,015	407,678	383,777	361,074	371,907	388,601
Growth (%)	35.9	15.2	-5.9	-5.9	3.0	4.5
India PV volumes (no of units)	375,133	546,967	585,587	572,098	582,918	598,423
Growth (%)	66.8	45.8	7.1	-2.3	1.9	2.7
India CV realization (Rs/unit)	1,335,076	1,612,972	1,910,043	1,922,570	1,970,486	1,994,208
Growth (%)	15.2	20.8	18.4	0.7	2.5	1.2
India PV realization (Rs/unit)	868,285	893,419	899,696	858,052	891,621	918,193
Growth (%)	16.8	2.9	0.7	-4.6	3.9	3.0
Standalone revenues (largely CVs)	472,637	657,573	733,031	694,190	732,837	774,951
Growth YoY (%)	56.6	39.1	11.5	-5.3	5.6	5.7
PV revenues	325,722	488,671	526,850	490,890	519,741	549,469
Growth YoY (%)	94.9	50.0	7.8	-6.8	5.9	5.7
Total India business revenue (Rs mn)	798,359	1,146,244	1,259,881	1,185,080	1,252,578	1,324,419
Growth YoY (%)	70.3	43.6	9.9	-5.9	5.7	5.7
Standalone EBITDA (largely CVs)	16,357	48,108	78,701	80,820	93,741	100,756
EBITDA margin (%)	3.5	7.3	10.7	11.6	12.8	13.0
PV EBITDA	9,150	27,862	33,770	33,570	37,586	39,555
EBITDA margin (%)	2.8	5.7	6.4	6.8	7.2	7.2
India business EBITDA	25,507	75,971	112,471	114,390	131,327	140,311
EBITDA margin (%)	3.2	6.6	8.9	9.7	10.5	10.6
Growth YoY (%)	135.1	197.8	48.0	1.7	14.8	6.8
Standalone EBIT (largely CVs)	(1,248)	30,440	58,532	60,740	68,962	73,074
EBIT margin (%)	(0.3)	4.6	8.0	8.7	9.4	9.4
PV EBIT	(11,265)	5,552	10,270	4,580	6,277	5,741
EBIT margin (%)	(3.5)	1.1	1.9	0.9	1.2	1.0
India business EBIT	(12,514)	35,991	68,802	65,320	75,239	78,815
EBIT margin (%)	(1.6)	3.1	5.5	5.5	6.0	6.0

Source: Company, Emkay Research

Exhibit 13: ...(contd) revenue model

JLR Business (£ mn)	FY22	FY23	FY24	FY25	FY26E	FY27E
JLR volumes (ex-CJLR)	294,182	321,362	401,303	400,898	392,089	392,089
Growth YoY (%)	-15.4	9.2	24.9	-0.1	-2.2	0.0
JLR Realization (£/unit)	62,274	70,976	72,252	72,240	70,073	70,774
Growth YoY (%)	9.7	14.0	1.8	0.0	-3.0	1.0
JLR Revenue	18,320	22,809	28,995	28,961	27,475	27,750
Growth YoY (%)	-7.2	24.5	27.1	-0.1	-5.1	1.0
JLR EBITDA	1,896	2,571	4,620	4,151	3,382	3,524
EBITDA margin (%)	10.3	11.3	15.9	14.3	12.3	12.7
JLR EBIT (incl China JV)	(48)	529	2,445	2,474	1,747	1,754
EBIT margin (%)	-0.3	2.3	8.4	8.5	6.4	6.3
JLR net debt/(cash)	3,199	2,997	732	(278)	(339)	(552)
Net Debt/EBITDA (x)	1.7	1.2	0.2	(0.1)	(0.1)	(0.2)
Net D/E (x)	0.7	0.7	0.1	(0.0)	(0.0)	(0.0)
JLR capex	2,036	2,353	3,263	3,790	3,800	3,192
JLR FCF	(1,156)	519	2,269	1,478	(528)	281

Consolidated Financials (Rs mn)	FY22	FY23	FY24	FY25	FY26E	FY27E
India revenue	798,359	1,146,244	1,259,881	1,185,080	1,252,578	1,324,419
JLR revenue	1,864,976	2,213,424	2,870,505	3,113,308	2,953,554	2,983,089
Consolidated revenue	2,784,536	3,459,670	4,340,160	4,440,521	4,478,910	4,594,941
Growth YoY (%)	11.5	24.2	25.5	2.3	0.9	2.6

India EBITDA	55,119	68,801	121,340	105,088	130,399	130,545
JLR EBITDA	193,013	249,494	457,380	446,233	363,590	378,862
Consolidated EBITDA	248,132	318,296	578,720	551,320	493,989	509,407
Growth YoY (%)	-18.8	28.3	81.8	-4.7	-10.4	3.1

EBITDA margin (%)						
India	6.9	6.0	9.6	8.9	10.4	9.9
JLR	10.3	11.3	15.9	14.3	12.3	12.7
Consolidated EBITDA margin (%)	8.9	9.2	13.3	12.4	11.0	11.1

Consol EBIT	(225)	69,692	306,330	318,760	262,126	257,636
Consol PBT	(62,807)	13,769	287,310	330,370	268,601	280,498
Consol EPS (Rs)	(28.0)	1.9	86.2	61.2	56.1	59.0

Consol Net Debt	1,008,381	698,066	384,402	-55,340	-18,095	4,125
Consol FCF	-6,555	175,774	367,328	260,340	41,420	51,121
ROE (%)	(21.5)	1.6	77.8	22.4	16.5	15.1
ROCE (%)	1.4	5.9	37.9	20.2	16.7	16.0

Source: Company, Emkay Research

Exhibit 14: We cut FY26E/27E consol EPS by ~15%, to factor in the weaker outlook/profitability at JLR

(Consolidated)	FY25		FY26E				FY27E			
	Actual	%YoY	Earlier	Revised	%Change	%YoY	Earlier	Revised	%Change	%YoY
JLR volume, excl China JV (no of units)	400,898	(0.1)	392,089	392,089	-	-2.2	392,089	392,089	-	0.0
Standalone volume – India CVs (no of units)	361,074	(5.9)	378,948	371,907	(1.9)	3.0	396,860	388,601	(2.1)	4.5
Consol Revenue	4,396,950	1.3	4,501,085	4,478,910	(0.5)	1.9	4,618,999	4,594,941	(0.5)	2.6
Consol EBITDA	551,320	(4.7)	550,859	493,989	(10.3)	-10.4	568,014	509,407	(10.3)	3.1
Consol Margin (%)	12.5	(80)bps	12.2	11.0	(121)bps	(12)bps	12.3	11.1	(121)bps	1bps
Consol PAT	225,030	(31.9)	241,232	206,272	(14.5)	-8.3	253,984	217,015	(14.6)	5.2
Consol Dil Adj EPS (Rs)	61.2	(29.1)	65.6	56.1	(14.5)	-8.3	69.0	59.0	(14.6)	5.2
Standalone (Rs mn)	FY25		FY26E				FY27E			
	Actual	%YoY	Earlier	Revised	%Change	%YoY	Earlier	Revised	%Change	%YoY
Volume	361,074	(5.9)	378,948	371,907	(1.9)	3.0	396,860	388,601	(2.1)	4.5
Revenue	694,190	(5.3)	754,578	732,837	(2.9)	5.6	798,537	774,951	(3.0)	5.7
EBITDA	80,820	2.7	96,522	93,741	(2.9)	16.0	103,822	100,756	(3.0)	7.5
Margin (%)	11.6	91bps	12.8	12.8	(0)bps	10bps	13.0	13.0	0bps	2bps
PAT	58,480	9.3	66,829	64,909	(2.9)	11.0	69,082	66,808	(3.3)	2.9
Adj EPS (Rs)	15.3	9.3	17.4	16.9	(2.9)	11.0	18.0	17.4	(3.3)	2.9
India PV (Rs mn)	FY25		FY26E				FY27E			
	Actual	%YoY	Earlier	Revised	%Change	%YoY	Earlier	Revised	%Change	%YoY
Volume	572,098	(2.3)	582,918	582,918	-	1.9	598,423	598,423	-	2.7
Revenue	490,890	(6.8)	519,741	519,741	-	5.9	549,469	549,469	-	5.7
EBITDA	33,570	(0.6)	37,586	37,586	-	12.0	39,555	39,555	-	5.2
Margin (%)	6.8	43bps	7.2	7.2	0bps	6bps	7.2	7.2	0bps	(0)bps
PAT	7,140	(34.3)	9,694	9,694	-	35.8	9,850	9,850	-	1.6
Adj EPS (Rs)	0.8	(34.3)	1.0	1.0	-	35.8	1.0	1.0	-	1.6
JLR (£)	FY25		FY26E				FY27E			
	Actual	%YoY	Earlier	Revised	%Change	%YoY	Earlier	Revised	%Change	%YoY
Volume	400,898	(0.1)	392,089	392,089	-	(2.2)	392,089	392,089	-	-
Revenue	28,961	(0.1)	27,475	27,475	-	(5.1)	27,750	27,750	-	1.0
EBITDA	4,151	(10.2)	3,877	3,382	(12.8)	(18.5)	4,024	3,524	(12.4)	4.2
Margin (%)	14.3	(160)bps	14.1	12.3	(180)bps	(14)bps	14.5	12.7	(180)bps	3bps
PAT	1,646	(36.1)	1,687	1,334	(20.9)	(18.9)	1,692	1,359	(19.7)	1.9
Adj EPS (GBP)	1.1	(36.1)	1.1	0.9	(20.9)	(18.9)	1.1	0.9	(19.7)	1.9

Source: Company, Emkay Research

Exhibit 15: We revise our SoTP-based TP downward by 6.3% to Rs750

SOTP-based valuation	Basis of valuation	Equity value (Rs mn)	Equity value (Rs/sh)	Contribution to SOTP (%)	Remarks
India CV	EV/EBITDA: 11x	1,069,546	291	38	Similar to EV/EBITDA multiple for AL
India PV, including EV	EV/Sales: 1.3x	740,484	201	26	20% discount to MSIL's multiple of ~1.7x EV/Sales
JLR	EV/EBITDA: 1.6x	646,565	176	23	In line with EV/EBITDA valuation of European peers
JLR-China JV	EV/EBITDA: 4x	8,458	2	0	Stake stands at 50%
Tata Sons	NAV: 1x	80,450	22	3	Holding company discount at 80%, as stake may not be monetized
Tata Capital	Market Cap	169,200	46	6	20% discount to Market Cap (based on media reports)
Tata Technologies	Market Cap	130,156	35	5	20% discount to CMP
Total (Rounded off)		750			

Source: Company, Emkay Research

Tata Motors: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Revenue	3,459,670	4,340,160	4,396,950	4,478,910	4,594,941
Revenue growth (%)	24.2	0	1.3	1.9	2.6
EBITDA	318,296	578,720	551,320	493,989	509,407
EBITDA growth (%)	28.3	0	(4.7)	(10.4)	3.1
Depreciation & Amortization	248,604	272,390	232,560	231,862	251,772
EBIT	69,692	306,330	318,760	262,126	257,636
EBIT growth (%)	0	0	4.1	(17.8)	(1.7)
Other operating income	-	-	-	-	-
Other income	46,332	56,920	62,440	63,064	71,263
Financial expense	102,255	75,940	50,830	56,590	48,400
PBT	13,769	287,310	330,370	268,601	280,498
Extraordinary items	16,807	(10,020)	4,560	0	0
Taxes	7,041	(40,240)	105,020	62,009	63,163
Minority interest	(2,756)	(4,077)	(3,190)	(3,190)	(3,190)
Income from JV/Associates	3,364	6,998	2,870	2,870	2,870
Reported PAT	24,143	320,451	229,590	206,272	217,015
PAT growth (%)	0	0	(28.4)	(10.2)	5.2
Adjusted PAT	7,336	330,471	225,030	206,272	217,015
Diluted EPS (Rs)	1.9	86.2	61.2	56.1	59.0
Diluted EPS growth (%)	0	0	(29.1)	(8.3)	5.2
DPS (Rs)	2.0	6.0	6.0	6.8	7.0
Dividend payout (%)	31.7	7.2	9.6	12.1	11.8
EBITDA margin (%)	9.2	13.3	12.5	11.0	11.1
EBIT margin (%)	2.0	7.1	7.2	5.9	5.6
Effective tax rate (%)	51.1	(14.0)	31.8	23.1	22.5
NOPLAT (pre-IndAS)	34,056	349,234	217,431	201,612	199,621
Shares outstanding (mn)	3,830	3,833	3,679	3,679	3,679

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Share capital	7,660	7,665	7,360	7,358	7,358
Reserves & Surplus	445,558	841,515	1,154,080	1,335,412	1,526,757
Net worth	453,218	849,180	1,161,440	1,342,771	1,534,115
Minority interests	72,777	81,759	66,100	69,290	72,480
Non-current liab. & prov.	(37,777)	(119,557)	(55,070)	(138,336)	(225,291)
Total debt	1,256,605	985,001	624,990	632,562	467,442
Total liabilities & equity	1,744,823	1,796,384	1,797,460	1,906,287	1,848,747
Net tangible fixed assets	729,760	621,620	565,388	825,084	1,009,528
Net intangible assets	504,621	504,621	504,621	504,621	504,621
Net ROU assets	-	-	-	-	-
Capital WIP	142,745	356,984	658,060	606,502	620,286
Goodwill	8,406	8,603	8,950	8,950	8,950
Investments [JV/Associates]	60,725	60,725	60,725	63,725	66,725
Cash & equivalents	573,222	627,053	704,175	671,502	481,162
Current assets (ex-cash)	1,211,477	1,318,033	1,134,730	1,247,198	1,241,742
Current Liab. & Prov.	1,564,145	1,779,266	1,917,200	2,099,306	2,162,279
NWC (ex-cash)	(352,667)	(461,233)	(782,470)	(852,108)	(920,537)
Total assets	1,744,823	1,796,384	1,797,460	1,906,287	1,848,747
Net debt	683,383	357,948	(79,185)	(38,940)	(13,720)
Capital employed	1,744,823	1,796,384	1,797,460	1,906,287	1,848,747
Invested capital	968,130	751,622	374,500	564,557	680,573
BVPS (Rs)	118.3	221.6	315.7	365.0	417.0
Net Debt/Equity (x)	1.5	0.4	(0.1)	-	-
Net Debt/EBITDA (x)	2.1	0.6	(0.1)	(0.1)	-
Interest coverage (x)	1.1	4.8	7.5	5.7	6.8
RoCE (%)	5.9	37.9	20.2	16.7	16.0

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
PBT (ex-other income)	33,939	279,551	387,550	271,471	283,368
Others (non-cash items)	44,518	25,352	(56,840)	0	0
Taxes paid	(31,790)	(45,163)	(39,910)	(145,276)	(150,118)
Change in NWC	(31,271)	73,252	81,560	66,772	67,699
Operating cash flow	353,880	679,154	631,020	481,420	501,121
Capital expenditure	(178,107)	(311,825)	(370,680)	(440,000)	(450,000)
Acquisition of business	-	-	-	-	-
Interest & dividend income	10,199	25,394	24,840	0	0
Investing cash flow	(168,042)	(228,281)	(475,940)	(440,000)	(450,000)
Equity raised/(repaid)	34,737	819	(280)	0	0
Debt raised/(repaid)	(202,397)	(266,965)	(104,520)	7,572	(165,120)
Payment of lease liabilities	0	0	0	0	0
Interest paid	(93,360)	(93,323)	(58,140)	(56,590)	(48,400)
Dividend paid (incl tax)	(1,409)	(10,591)	(24,920)	(22,075)	(24,941)
Others	0	0	(16,947)	0	0
Financing cash flow	(262,429)	(370,060)	(204,807)	(71,093)	(238,461)
Net chg in Cash	(76,591)	80,813	(49,727)	(29,673)	(187,340)
OCF	353,880	679,154	631,020	481,420	501,121
Adj. OCF (w/o NWC chg.)	385,151	605,902	549,460	414,647	433,422
FCFF	175,774	367,328	260,340	41,420	51,121
FCFE	83,717	316,783	234,350	(15,170)	2,721
OCF/EBITDA (%)	111.2	117.4	114.5	97.5	98.4
FCFE/PAT (%)	346.8	98.9	102.1	(7.4)	1.3
FCFF/NOPLAT (%)	516.1	105.2	119.7	20.5	25.6

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY23	FY24	FY25	FY26E	FY27E
P/E (x)	108.9	8.2	11.0	12.2	11.6
P/CE(x)	10.3	4.4	5.5	5.8	5.4
P/B (x)	5.8	3.1	2.2	1.9	1.6
EV/Sales (x)	1.0	0.7	0.6	0.6	0.5
EV/EBITDA (x)	10.4	5.2	4.4	5.0	4.9
EV/EBIT(x)	47.5	9.8	7.7	9.5	9.8
EV/IC (x)	3.4	4.0	6.5	4.4	3.7
FCFF yield (%)	5.3	12.3	10.6	1.7	2.0
FCFE yield (%)	3.3	12.5	9.3	(0.6)	0.1
Dividend yield (%)	0.3	0.9	0.9	1.0	1.0
DuPont-RoE split					
Net profit margin (%)	0.2	7.6	5.1	4.6	4.7
Total asset turnover (x)	1.8	4.8	2.4	2.4	2.4
Assets/Equity (x)	4.3	2.1	1.8	1.5	1.3
RoE (%)	1.6	77.8	22.4	16.5	15.1
DuPont-RoIC					
NOPLAT margin (%)	1.0	8.0	4.9	4.5	4.3
IC turnover (x)	3.0	11.5	7.8	9.5	7.4
RoIC (%)	3.0	92.9	38.6	42.9	32.1
Operating metrics					
Core NWC days	(37.2)	(38.8)	(65.0)	(69.4)	(73.1)
Total NWC days	(37.2)	(38.8)	(65.0)	(69.4)	(73.1)
Fixed asset turnover	1.0	2.4	1.2	1.1	1.0
Opex-to-revenue (%)	25.3	23.8	25.6	26.5	26.4


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
10-Jun-25	732	800	Buy	Chirag Jain
14-May-25	699	800	Buy	Chirag Jain
16-Apr-25	616	800	Buy	Chirag Jain
15-Apr-25	622	800	Buy	Chirag Jain
11-Mar-25	648	950	Buy	Chirag Jain
30-Jan-25	697	950	Buy	Chirag Jain
10-Jan-25	775	950	Buy	Chirag Jain
09-Jan-25	780	950	Buy	Chirag Jain
18-Dec-24	756	1,000	Buy	Chirag Jain
10-Nov-24	805	1,000	Buy	Chirag Jain
08-Oct-24	920	1,175	Buy	Chirag Jain
18-Sep-24	962	1,175	Buy	Chirag Jain
02-Aug-24	1,097	1,175	Add	Chirag Jain
10-Jul-24	1,006	1,050	Add	Chirag Jain
12-Jun-24	989	1,050	Add	Chirag Jain
11-May-24	1,047	950	Reduce	Chirag Jain
18-Apr-24	971	950	Reduce	Chirag Jain
04-Mar-24	987	950	Reduce	Chirag Jain
03-Feb-24	879	925	Add	Chirag Jain
10-Jan-24	808	900	Add	Chirag Jain

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of June 17, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of June 17, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the June 17, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Gaurav Narkar (gaurav.narkar@emkayglobal.com) use and downloaded at 06/18/2025 02:41 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

June 17, 2025 | 13

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.